/
ABCC8 aka SUR1 Gene Curation

ABCC8 aka SUR1 Gene Curation

  1. Summary table:

Disease

Inheritance

Molecular mechanism

Disease

Inheritance

Molecular mechanism

Monogenic diabetes

Autosomal dominant (primary inheritance pattern)

Activating (GOF)

Monogenic diabetes

Autosomal recessive (rare)

Partially activating + LOF

Familial hyperinsulinism

Autosomal recessive (Primary inheritance)

LOF

Familial hyperinsulinism

Autosomal dominant (less common)

Dominant Negative

Familial hyperinsulinism (FOCAL)

Paternally inherited LOF variant + loss of maternal allele in pancreatic tissue

*a single LOF variant is NOT diagnostic for Focal disease per genereviews, due to potential to miss a maternal variant

 

 

  1. Katie Russell is a Broad expert on ABCC8 - she shared these slides https://docs.google.com/presentation/d/1Lw5xnS3-EUYBMeSBMQ9euHRG45imqOWDTQ6KRSdGiw8/edit#slide=id.p Her summary -

    image-20240726-151710.png
    1. CHI

      1. AR - caused by LOF

        1. Some patients with somatic UPD of the pancreas of carriers can develop focal CHI

      2. AD - dominant negative

  2. Did not curate Semidominant monogenic diabetes (MODY) - definitive (GOF / activating mutations by Monogenic diabetes GCEP.); however, there are recessive cases with 1 partially activating and 1 inactivating mutation. This is aka permanent neonatal diabetes. They note that inactivating LOF variants cause hyperinsulinemic hypoglycemia.

  3. Did not curate pulmonary arterial hypertension - not well established per above

Disease

Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia

Disease

Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia

Inheritance

autosomal recessive

Prevalence

 

Source:

Rapid or full curation?

Rapid
Full

ClinGen / GenCC / BabySeq / HGMD / OMIM

Not in ClinGen. GenCC - Definitive Ambry (Semidominant); Strong (Invitae; AR and AD) - no conflicts - sufficent to say there is enough evidence for a strong GDA.

Clinical Validity Scoring Notes and points

n/a - GenCC provides sufficent evidence that there is a strong association

Source:

Clinical Validity Points Total

 

Source:

Clinical Validity Classification

Definitive (12pts)

Strong (12pts)

Moderate (7-11pts)

Limited (0.1-6pts)

No genetic evidence

Refuted

Disputed

Strong

 

Molecular Mechanism

Loss of function

Gain of function

Dominant negative

Unknown

Other

Loss of function

 

  1. NM_000352.3(ABCC8):c.4014G>A(W1338*) - 24932607_Durmaz_2014

    1. Homozygous in patient with congenital hyperinsulinism, diffuse HI determined via histological findings from near-total pancreatecomy at 2 months of age.

  2. M_000352.3(ABCC8):c.3868-1G>A - 23345197_Kapoor_2013

    1. Homozygous in a patient with Congenital hyperinsulism, diffuse HI determined via histological findings from near-total pancreatecomy.

  3. NM_000352.3(ABCC8):c.3509delT(L1170Rfs*38) - 24686051_Demirbilek_2014

    1. Homozygous in patient w/ congenital hyperinsulism HI that responded to octreotide, developmental delay, and ectodermal dysplasia.

KO mouse model 10734066_Seghers_2000

  • SUR1 knockout mice were generated by inserting a puromycin resistance gene into ABCC8 exon 2. Patch clamp assays were used to show that SUR1-/- mice exhibit no K+ current (Fig 2A) and show spontaneous Ca2+ action potentials (Fig 2B), which recapitulates function data from KATP in patient cells. SUR1-/- mice exhibit mild glucose intolerance in response to glucose challenge (Fig 5) and transient neonatal hypoglycemia (Fig 6), however, the mice do not recapitulate the full human hypoglycemic phenotype.

 

Focal CHI -

  • Caused by paternally inherited LOF variant and loss of the maternal allele (usually due to UPD in the pancreas)

Penetrance

Complete (100%)

High (≥80%)

Moderate  (<80% and >20%)

Low (≤20%)

(list source/PMID)

Incomplete

Age of Onset

Congenital

Pediatric

Adolescent

Adulthood

Late adulthood

(list source/PMID)

 

Severity

 

Clinical Features

inappropriate secretion of insulindespite low blood glucose, which can result in irreversible braindamage if not promptly treated (Helleskov et al., 2017). Thecondition has a variable phenotype usually presenting during the neonatal period or infancy with seizures and/or coma and alarge birth weight due to high levels of insulin acting as a growth factor in utero. (Defranco_2020_32027066)

Sources:

HPO Terms

https://hpo.jax.org/app/

 

Gene SOPs & Notes

 

Curation Summary

The ABCC8 gene is associated with two different diseases with multiple inheritance patterns. Monogenic diabetes, which also includes known as transient or permanent neonatal diabetes of infancy, is primarily an autosomal dominant disorder caused by activating mutations. Autosomal recessive cases with a partially activating mutation and an inactivating mutation have also been reported. It is characterized by the onset of hyperglycemia within the first six months of life with partial or complete insulin deficiency. Clinical manifestations at the time of diagnosis include intrauterine growth restriction, hyperglycemia, glycosuria, osmotic polyuria, severe dehydration, and failure to thrive (PMID: 20301620, 17668386).

Familial hyperinsulinism, also known as congenital hyperinsulinism or hyperinsulinemic hypoglycemia, is primarily an autosomal recessive disorder caused by inactivating (loss-of-function; LOF) variants; however, autosomal dominant cases have also been described and is caused by dominant-negative variants (PMID: 32027066, 20301549, 24814349, 26092864). Furthermore, focal hyperinsulinism is also described in individuals with a paternally inherited inactivating (LOF) mutation and loss of the maternal allele in the pancreatic tissue. Familial hyperinsulinism is characterized by hypoglycemia due to an inappropriate secretion of insulin despite low blood glucose. It can range from mild to severe and present from the newborn period to childhood. In the neonatal period or infancy, it can present with seizures and/or coma, as well as large birth weight (PMID: 20301549, 32027066).

Case ID, Curator name, Date, Jira ticket link

AO 07.26.24, 47230812301136

 

Disease

Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia

Disease

Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia

Inheritance

autosomal dominant

Prevalence

 

Rapid or full curation?

Rapid
Full

ClinGen / GenCC / BabySeq / HGMD / OMIM

Not in ClinGen.

GenCC:

  • Definitive for Semidominant hyperinsulinemic hypoglycemia, familial, 1 by Ambry

  • Definitive for AD hyperinsulinemic hypoglycemia, familial, 1 by Illumina

  • Strong for AD hyperinsulinemic hypoglycemia, familial, 1 by Invitae

Clinical Validity Scoring Notes and points

n/a - not needed, no conflicts in GenCC

Clinical Validity Points Total

n/a - not needed, no conflicts in GenCC

 

Clinical Validity Classification

Definitive based on GenCC submissions

Molecular Mechanism

Dominant-negative

Saint-Martin 2015 PMID: 24814349

  • De novo variants include Leu511M, L891P is de novo, L1390P, Asn1481Ile, Asp1506Glu, Ile1512Ser.

  • Nine missense (L511M, E825K, K890T, L891P, G1379S, A1459V, N1481I, D1506E, I1512S) ABCC8 mutations were subjected to in vitro expression studies testing traffic efficiency and responses of mutant channels to activation by MgADP and diazoxide. Eight of the 9 missense mutations exhibited normal trafficking (all except G1379S). Seven of the 8 mutants reaching the plasma membrane had dramatically reduced response to MgADP or to diazoxide(<10% of wild-type response) - all except K890T. Expression levels normal, but reduced response - supports dominant negative effect.

Nessa 2015 PMID: 26092864

  • 7 different dominant variants described, unresponsive to diazoxide treatment

  • 3 variants (D1506E, M1514K, A113V) were co-expressed with WT to investigate a dominant negative effect. 2 experiments performed - 6Rb+ flux and whole-cell patch-clamp. In both of these assays, all the mutants tested impaired the DZX-activated currents but the degree of the effect varied between mutants. However, in all cases it reduced flux and current by over 50% (Fig. 6).

Huopio 2000 11018078

  • E1506K found het in 7 patients with CHI and their mothers.All patients had a mild form of CHI that could be managed long-term diazoxide treatment. Mothers did seem to be affected.

Penetrance

(list source/PMID)

 

Age of Onset

(list source/PMID)

 

Severity

 

Clinical Features

Same as AR CHI

HPO Terms

https://hpo.jax.org/app/

 

Gene SOPs & Notes

 

Curation Summary

See above under AR CHI

Case ID, Curator name, Date, Jira ticket link

AO 07.26.24